Key result
Jiangya Tongluo formula lowered blood pressure, 24-h urine protein, serum creatinine, and BUN in rats with hypertensive nephrosclerosis, possibly by upregulating ADM and antagonizing Ang II.
Why the study?
Does Jiangya Tongluo formula improve renal function and blood pressure in a rat model of hypertensive nephrosclerosis?
RCT (n=28)
randomized
Does Jiangya Tongluo formula improve renal function and blood pressure in a rat model of hypertensive nephrosclerosis?
Jiangya Tongluo formula demonstrates renal protective and antihypertensive effects in a rat model of hypertensive nephrosclerosis, potentially mediated by upregulating intrarenal adrenomedullin and antagonizing angiotensin II.
Does not support clinical use in hypertensive nephrosclerosis; leaves open efficacy of traditional formulas pending human trials.
We investigated the effect of Jiangya Tongluo (JYTL) formula on renal function in rats with hypertensive nephrosclerosis. A total of 21 spontaneously hypertensive rats (SHRs) were randomized into 3 groups: valsartan (10 mg/kg/d valsartan), JYTL (14.2 g/kg/d JYTL), and a model group (5 mL/kg/d distilled water); Wistar Kyoto rats comprised the control group (n = 7, 5 mL/kg/d distilled water). Treatments were administered by gavage every day for 8 weeks. Blood pressure, 24-h urine protein, pathological changes in the kidney, serum creatinine, and blood urea nitrogen (BUN) levels were estimated. The contents of adrenomedullin (ADM) and angiotensin II (Ang II) in both the kidney and plasma were evaluated. JYTL lowered BP, 24-h urine protein, serum creatinine, and BUN. ADM content in kidneys increased and negatively correlated with BP, while Ang II decreased and negatively correlated with ADM, but there was no statistically significant difference of plasma ADM between the model and the treatment groups. Possibly, activated intrarenal renin-angiotensin system (RAS) plays an important role in hypertensive nephrosclerosis and the protective function of ADM via local paracrine. JYTL may upregulate endogenous ADM level in the kidneys and antagonize Ang II during vascular injury by dilating renal blood vessels.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2015) conducted an RCT in hypertensive nephrosclerosis (n=28). Jiangya Tongluo (JYTL) formula vs. Valsartan (10 mg/kg/d) and distilled water (model group) was evaluated on Renal function (blood pressure, 24-h urine protein, serum creatinine, BUN, ADM, Ang II). Jiangya Tongluo formula lowered blood pressure, 24-h urine protein, serum creatinine, and BUN in rats with hypertensive nephrosclerosis, possibly by upregulating ADM and antagonizing Ang II.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: